Early research suggests increased fat in the diet of SMA mouse model could harm liver function

As a part of our engagement with research into diet we came across this novel work and thought that general SMA population would be interested in the data.

Recent evidence has shown that increased fat in the diet of SMA mouse model cause damaging changes in the liver function. This current research shows further that by reducing the fat content in the diet reduces the damage to the liver and increases the life span of the mouse, in some cases doubling it!

The study clearly highlights that there is tentative benefit to reducing daily fat intake as it shifts metabolic processes away from production of substances deemed to be toxic to SMA patients.

The full article can be found here.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more